Related Experiment Videos
Primary central nervous system lymphomas: a 30-year experience at a single institution
J D Nuckols1, K Liu, J L Burchette
1Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.
Summary
Primary central nervous system lymphoma (PCNSL) is a rare, aggressive cancer. Concurrent immunosuppression significantly predicts poor outcomes in PCNSL patients, especially those with AIDS.
Area of Science:
- Oncology
- Neurology
- Immunology
Background:
- Primary central nervous system lymphoma (PCNSL) is a rare malignancy with increasing incidence.
- Large B-cell lymphoma constitutes the majority of PCNSL cases.
Purpose of the Study:
- To review clinical, histologic, and immunohistochemical data of PCNSL cases.
- To classify PCNSL using the REAL classification system.
- To identify prognostic indicators for PCNSL outcomes.
Main Methods:
- Retrospective review of 64 PCNSL cases from Duke University Medical Center (since 1968).
- Tumor classification using the Revised European-American Lymphoma (REAL) classification system.
- Analysis of patient demographics, tumor characteristics, and survival data.
Main Results:
- Large B-cell lymphoma accounted for 81% of PCNSL cases; T-cell lymphomas were rare.
- Epstein-Barr virus was detected in 75% of tested immunocompromised patients.
- Overall survival was poor (median 158 days); concurrent immunosuppression was a strong predictor of poor outcome.
- AIDS patients had significantly shorter median survival (65 days) compared to immunocompetent patients (217 days).
Conclusions:
- Concurrent immunosuppression is the strongest predictor of poor outcome in PCNSL.
- PCNSL in AIDS patients has a particularly dismal prognosis.
- Further research is needed to improve treatment strategies and outcomes for PCNSL, especially in immunocompromised individuals.